Create a free Packaging World account to continue reading

New unit-dose spray device for cancer patients

Single unit-dose device disperses a fine mist under the tongue for breakthrough cancer pain.

On March 26, INSYS Therapeutics, Inc., a Phoenix-based specialty pharmaceutical company, and drug delivery firm Aptar Pharma, announced the U.S. launch of INSYS Therapeutics’ SUBSYSTM, which uses an Aptar Pharma sublingual (under the tongue) Unit-Dose Spray (UDS) device for breakthrough cancer pain in patients age 18 and older and who are already tolerant to opioid therapy.

The new dosage form/single unit-dose delivery device disperses a fine mist over a broad sublingual area. The spray is indicated for the treatment of breakthrough cancer pain in opioid-tolerant adult patients who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Breakthrough cancer pain occurs in patients with cancer and is often defined as a temporary flare in pain that can be quite severe. These flares occur in the context of background pain that is otherwise usually controlled with opioids.

Your liquid filling supplier shortlist starts here
30+ suppliers across sachets, pouches, bag-in-box, and stick packs. Free, no search required.
Read More
Your liquid filling supplier shortlist starts here
Need help with your packaging project?
We’ve done the legwork to identify and vet experienced packaging and processing consultants you can contact directly for your next project. Decades of combined experience in packaging line engineering, machinery selection, package and materials development, and food processing operations.
See your advisor options now.
Need help with your packaging project?